Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ludwig, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ludwig, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:181-182, 2004
© 2004 European Society for Medical Oncology

European Society of Medical Oncology membership survey

Heinz Ludwig

The first 10% of the full text of this article appears below.

Market research is a popular instrument used by industry to learn more about the profile and expectations of potential clients. Scientific and professional societies, the European Society of Medical Oncology (ESMO) included, also need to be acquainted with their members’ characteristics—their background, working conditions, activities, needs and expectations. These were among the considerations that prompted ESMO to undertake a membership survey. Last year, a questionnaire was designed and sent out by mail to 3457 ESMO members of whom 393 (11.4%) returned the completed files. Although the response rate was . . . [Full Text of this Article]

What is the profile of ESMO members?

How do ESMO members appraise ESMO activities?

What do members expect of ESMO?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. D. Hainsworth, D. R. Spigel, S. Litchy, and F. A. Greco
Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study
J. Clin. Oncol., August 1, 2006; 24(22): 3548 - 3554.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. A. Kosmidis, H. Ludwig, and H. Mellstedt
ESMO at 30: Mission ongoing
Ann. Onc., September 1, 2005; 16(9): 1411 - 1412.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H. Ludwig
A Foundation for the future
Ann. Onc., January 1, 2005; 16(1): 3 - 3.
[Full Text] [PDF]